putting patients first - microsoft · the projects we fund include collaborations in more than 40...
TRANSCRIPT
![Page 1: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/1.jpg)
Cure Brain Cancer’s Research Vision
PUTTING PATIENTS FIRST
![Page 2: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/2.jpg)
2 Foreword
4 Achievements
6 The current landscape: catalysts
7 Mission
8 Our strategy
•Approach
•Collaborationandborderlessresearch
•Therighttreatmentfortherightpatient
•Everypatientonatrial
•Ourresearchprograms
•Empoweringpatients
17 Grants
18 Scientific Advisory Committee
19 Conclusion: hope for the future
Contents
• Accelerated access toeffectivetreatments.
• Empowering patients: patientsareatthecentre ofeverythingwedo.
• International collaboration: braincancerresearchneeds tobeborderless.
• Weultimatelyaimtocreateasystemofresearchthatisinherentlysustainable.
What makes us different
• Wearechallengingthenorm.
• Wearenotpreparedtoacceptthestatusquo.
• Ourquestionisnot‘why?’ but‘whynot?’
• Weencouragelateralthinkingandcollaboration.
• Wearetakingmorerisksandexpectinggreaterrewards.
• Ourcompassionisfierce.
VISION VALUES
1PUTTING PATIENTS FIRST
![Page 3: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/3.jpg)
FOREWORD
The global brain cancer community has drawn a line in the sand: the prognosis for patients is unacceptable. We have reached a tipping point and are on the brink of some revolutionary changes. The world is uniting to overcome the complex and systemic barriers holding back advances. Cure Brain Cancer is a key player in this global movement and we have developed a disruptive approach that will give patients early access to promising treatments, and have built a robust research model that is attractive and compelling to fund.
Thelast30yearshaveseensomeenormousscientificandtechnological
advances;3Dprinting,nanotechnology,cloning,thediscoveryoftheHiggs
Bosonorso-called“God”particle,decodingthehumangenome,exploring
Mars.Andyet,treatingbraincancereffectivelyremainsachallengeand
survivalrateshavehardlychangedinthesedecadesofgreatadvancement.
AsPresidentObamasaidwhenlaunchingtheBRAINmappinginitiativeinthe
US,“ashumans,wecanidentifygalaxieslightyearsaway…wecanstudy
particlessmallerthananatom.Butwestillhaven’tunlockedthemystery
ofthethreepoundsofmatterthatsitsbetweenourears.”
Braincancerisaninsidiousdisease.Currenttreatmentsareundisputedly
ineffectiveformostpeople.Inanageofever-advancingunderstandingabout
cancerandgenetics,braincancercontinuestokillmorechildreninAustralia
thananyotherdisease.Wefeelthatthisisunacceptable.
Thegoodnewsisthatalotofthegroundworktochangethishasalready
beendone;infact,therehasbeenanexplosionofunderstandinginbrain
cancerinrecentyears.Weareheartenedbythefactthattherehavebeen
significantadvancesinbasicscienceandtheresultsofthisarenowbeing
translatedfromthelabtotheclinic.Anewgenerationofbraincancer
treatmentsarebeinginvestigatedandtestedwhichhavegreatpotential
toimproveoutcomesforpeoplelivingwithbraincancer.Butthereisno
“magicbullet”andthereisstillworktodo.
We recognise that to solve a complex problem like brain cancer we need to do things differently; to think laterally and find smarter solutions that allow us to make breakthroughs much faster than traditional research methods allow. We aim to disrupt traditional and siloed practices, challenge the system and innovate to make this happen.
WhenIfirststartedatCureBrainCancerFoundationthecommunitywas
relativelydisparatewithseeminglynocriticalmass.Overthelastfewyears
Ihaveseenthiscompletelyshifttoaunified,focusedmovementthatis
gatheringmomentumacrossmanysectors.
We believe that the best medicine is personalised medicine; the right treatment for each patient.
Bytakingapan-cancerapproachtotreatments,wecanrepurposedrugs
whichareeffectiveinothercancerstouseonbraincancer,morequickly
identifynoveltargetsandusebigdatatoconnectmoleculartargetswith
existingclinicalknowledge.
Weknowthatpatientsreportbetterhealthoutcomeswhentheyparticipate
inclinicaltrials.WeareworkingtobringqualityclinicaltrialstoAustralia
sothatpatientscanaccessnewtreatmentsatthesametimeastheyare
availableglobally.Thisisakeypartofourmissiontoincreasesurvival,
butitwillalsoadvancemedicalresearchbybuildingAustralia’smedical
researchinfrastructure.
Thetimehasalreadycomeandgonetoputasidedifferences,share
informationandcollaborateratherthancompete.Iamhappytosaythatthis
isnowhappeninginbraincancerresearch.Forward-thinkingcollaborations
suchastheBrainCancerDiscoveryCollaborativehereinAustralia,aswellas
internationalpartnershipsbetweenresearchorganisationsandcharitiesare
speedingupprogress.Weneedtoworktogethertoensurethiscontinues,
buildingonoursuccessesaswellaslearningfromourmistakes.
We need to put patients at the centre of everything we do, empower them to advocate and influence the conversation about brain cancer.Ihavealreadymetsomanycourageouspeople
whospeakout,donate,fundraise,volunteerandsharetheirstoriestoraise
awarenessandfunds,andsomeofthemknowtheywillnotbenefit;
itwillcometoolateforthem.Theyaredoingitforfuturegenerations,
togivethemabetterchance.
Thesepeopledeservetreatmentoptionsandbetteroddsofsurvivingbeyond
fiveyearsthanjust20%.Theydeservetobeheardandnotmarginalised,just
becausetheyhavebeendiagnosedwithalowerincidencecancer.
Michelle Stewart, Head of Research, Cure Brain Cancer
32
Thereisnotimeforcomplacency,pessimismorprocrastination. It’stimetoputpatientsfirst.“
PUTTING PATIENTS FIRST
![Page 4: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/4.jpg)
ACHIEVEMENTS
In 2014-15 Cure Brain Cancer invested more than $2.65 million in research and committed an additional $8.91 million. The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries.
Through our inaugural 2014 grant round alone we committed $2.2 million for nine research projects, including two clinical trials. These projects include collaborations across 24 institutions, three states and four countries.
Our commitment to accelerating treatments to patients has seen us invest for the first time in five clinical trials in 2014/15 worth $4.1 million. These include international collaborations and Australian-grown interventions.
54 PUTTING PATIENTS FIRST
CureBrainCancersharesourvisionforthe BCDC;tohaveahighlyco-operativeAustralianbraincancerresearchcommunitygeneratingworld-classresultsanddrivingdiscovery intotheclinic.
- ProfTerranceJohns,Director,BrainCancerDiscoveryCollaborative
“
In2015werenewedourcommitmenttoourlong-termrelationshipwith
Associate Professor Kerrie McDonald and the Cure Brain Cancer Neuro-oncology Group at University of NSWtoprovideanadditionalfiveyears
ofpledgedfunding.TheChairpositionhasbeenrenamedastheChairof
BiomarkerandTranslationalResearchtoreflectthespecialityofthelab.
CureBrainCancercommittedtofundtheCure Brain Cancer John Trivett FellowshipinbraincancerinQueensland.Thepositionwillbeheldat
TheUniversityofQueenslandplacedwithintheInstituteforMolecular
BiosciencesorQueenslandBrainInstitutein2016.
In2014wecommittedanadditional$2.8millionovertwoyearstothe
Brain Cancer Discovery Collaborative,bringingourtotalcommitment
to$3.8millionoverthreeyears.TheBCDCallowsspecialistbraincancer
labstoshareresourcesandbecomemoreeffectiveasagroupthanthey
wouldinisolation.
GBM AGILE: A world-first, global adaptive clinical trial GBMAGILEisarevolutionarynewwayoftestinganddevelopingbrain
cancertreatments.Thisglobaladaptiveclinicaltrialhasbeenbrought
aboutbythebiggestcollaborationinthehistoryofbraincancer
research,inwhichCureBrainCancerhasplayedakeyrole.Withtrial
sitesduetoopeninAustralia,theUSandChina,thislearningsystem
willcutredtapeandhasthepotentialtodeliverfasterresultsandgive
patientsfasteraccesstonew,effectivetreatments.
Zero Childhood Cancer: Personalising treatments for children with cancer
TheZeroChildhoodCancerprogramisthefirstofitskindinAustralia
andwillgivehopetochildrenwiththeworstprognosis,thosewith
high-riskcancer,includingthosewithbraincancer.Thepersonalised
approachofthetrialaimstofindtherighttreatmentforeachchildto
increaseeffectivenessoftreatmentandreduceside-effects.
Immunotherapy Trial: Thistrialisaninternationalcollaborative
betweentheClinicalResearchInstituteandLudwigCancerResearch
Centre,partiallyfundedbyCureBrainCancer,whichwasthefirsttrialto
investigateanimmunotherapycheckpointinhibitorforthetreatmentof
braincancer.Thisclassoftherapyhasshownpromiseinothercancers.
KB004:TheantibodyKB004isanAustralianinnovationthat
CureBrainCancerhashelpedfundfromthelabtotheclinic.
VERTU:VERTUisanAustralianinitiativetriallingdrugsinGBMpatients
toseeifchemotherapycanbemademoreeffective.
![Page 5: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/5.jpg)
Precision Medicine
TheCancerGenomeAtlas(TCGA)wasaninitiativeaimedatgenerating
moleculardataonalargescaleaboutanumberoftumours.
ThefirstprojectundertakenbytheTCGAfocusedonbraincancer
andhasprovidedgenomicdataonthesetumoursthathasledtoa
significantlyincreasedunderstandingofthemutationsinthisdisease.
Therehavebeenanumberofrecentadvancesthathaveprovideda
greaterunderstandingofdifferentgenomicsubtypesofbraincancer,
suchaspaediatricbraincancer(medulloblastoma,PNETs),sotreatment
canbetailoredmorespecificallytoeachpatient.
Increased access to certain tumour types (including DIPG) through surgical advances and post-mortem access to tissue will provide significant opportunities to further study these tumours.
Thereisnowagreaterunderstandingofgenomicandproteinmarkers
thatapplyacrosscancertypes.Thedayiscomingwherewemayno
longerdefinecancerbythepartofthebodywhereitdevelops,butby
itsgenomicprofile.Forexample,certainmutationsinbreastcanceror
melanomamaybepresentinbraincancer,meaningthatthebraincancer
mayrespondtoeffectivetreatmentsinothercancers.Developmentof
drugsforthistypeofmutation-driventreatmentwillincrease.
Therehasbeenasignificantreductioninthecostofgenomeandexome
sequencing.Thismeansthatitispossibletogetincreasedaccessto
theseservicesinadiagnosticcapacityandalsoforthelargescale
collectionofthisinformation.
Innovativeclinicaltrialdesignallowsformoreeffectivedevelopment
oftreatments.ThisincludesGBMAGILE,whichusesanongoing
platformendorsedbytheFDA,designedsothattreatmentcanbe
adaptedfasterbasedonpatients’responseandthosethatworkcan
beidentifiedfaster.Clinicalresearchcanbedonefasterwithincreased
accuracyandatamuchlowercost,whichwillencouragemoreactivity
frombiopharmaceuticalcompanies.
THECURRENTLANDSCAPE:CATALYSTS
CureBrainCancerisanextraordinarypartnerinthecollaborativeeffortinbraincancerresearch.IamconvincedthattheireffortswillultimatelybenefitpatientsinAustraliaandaroundtheworld.
– ProfessorWebsterK.Cavenee,Ph.D,Director, LudwigInstituteforCancerResearch,SanDiego DistinguishedProfessor,UniversityofCaliforniaatSanDiego
“76 PUTTING PATIENTS FIRST
Cancer Immunotherapy
Therehavebeensignificantsurvivalimprovements
inothercancersusingimmunotherapies,suchas
checkpointblockade,antibody-drugconjugates,
CAR-Tanddendriticcells.Therearealsonovel
therapiesthatareshowingearlystagepromise.
Brainmetastasesfromothertypesofcancerhave
shownearlyresponsetoimmunotherapies,further
indicatingthattheremaybeaplaceforthese
treatmentsinprimarybraincancer.
Whileimmunotherapyisshowingpromise,the
costofproductionneedstobeconsideredso
that,ultimately,itcanbeaffordableandtherefore
accessibleforallpatients.
Not-for-profit groups
Manynot-for-profitgroupsaroundtheworldare
startingtoseethebenefitsofworkingtogetheronkey
projectsthatwilldelivergreaterimpactforpatients
thaniftheyworkedalone.Thisiscreatingsignificant
valuebyvirtueofscaleandpooledexpertise.
Here’s the problem:
• BraincancerkillsmorechildrenthananyotherdiseaseinAustralia.
• Itkillsmorepeopleunder40thananyothercancer.
• Only2in10peoplewillsurviveforfiveyearsandthathasbeen
thecaseforthelast30years.
• Wedon’tknowwhatcausesitandcurrenttreatmentisineffective.
• Ahugeincreaseinresearchfunding,incombinationwithredesigned
processes,willgiveustheanswerstoimprovesurvival.
CUREBRAINCANCER’SMISSION
Thereisnow,forthefirsttime,realhope ofextendingthelivesofpatientswith newtherapeuticapproaches;thisis wonderfulnewsforpatients.
– ProfessorInderM.Verma,Ph.D, Professor,LaboratoryofGenetics, TheSalkInstituteforBiologicalStudies
“
Our ten-year mission began in 2013: to improve five-year survival to from 20% to 50% by 2023.
Our research strategy is the foundation upon which we will achieve our mission.
![Page 6: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/6.jpg)
CureBrainCancer’sresearchstrategyisdesignedtogetnewtreatments
topatientsfasterbyfundingacrosstheentireresearchpathwayto
addresstargetedquestions,increaseaccesstotreatmentsforpatients
andremoveblockages.
Weknowthatexistingtreatmentssuchaschemotherapyandradiotherapy
donotworkformostpeopleandsurvivalratesforbraincancerhaven’t
improvedfor30years.Developingandtestingnovelandinnovative
treatmentsistheonlywaytochangethisandgivehopeofabetter
prognosistopeoplelivingwithbraincancer.
Weareworkingtocreateaccesstoclinicaltrialsforbothadultsandchildren
inAustralia,toimprovesurvivalratesbutalsotoreducetheharmofcurrent
treatmentoptions,thusimprovingqualityoflife.Ouraimisthatevery
persondiagnosedwithbraincancerinAustraliawillhaveaccesstonew
treatmentsthroughqualityclinicaltrials.
Wealsofundearlystageresearch,asthisisthefoundationuponwhich
therapeuticdiscoverycanoccur.
Year 12013/14
Year 22014/15
Year 32015/16
Values
3 year transition strategy
Establishment ofScientific Advisory
Committee.
Culture
Strategic Priorities
OperationalExcellence
Audit of brain cancerresearch and funding
systems.
New strategic direction,research strategy and
national operationsroll-out.
Engagement withstakeholders, influencersand Government aligned
to new strategy.
Communitymobilisation.
Mergers andcollaborations.
Momentum, awareness& fundraising increases.
Clinical trial results drivescience. More Australian
patients on trials. Raise $10m per annum.
Advocacy yieldsGovernment support.
Strategic fundraisingand engagement
programs.
New research investment.2 x clinical trials.
9 research projects funded.
Name change andnational re-brand.
Brain Cancer DiscoveryCollaborative in place.
OURSTRATEGY
What are we working to achieve?
• Ourmissionistoincreasefiveyearsurvival
fromthecurrent20%to50%by2023.
Toachievethis,wearefundingworld-class
researchtoacceleratenewtreatments
topatients.
Why are we doing this?
• Existingtreatmentsdonotworkformost
patientsandbraincancersurvivalrates
haven’timprovedfor30years.
• Wehaveseenhowresearchfundinghas
dramaticallyimprovedsurvivalratesin
othercancersinthistime,suchasbreast
andprostatecancer.Wewanttoemulate
theirsuccess.
• Braincancerkillsmorechildrenthanany
otherdiseaseandmorepeopleunder40
thananyothercancer.
Who are we doing this for?
• Patientsareatthecentreofeverything
wedoandourresearchactivityisdesigned
toacceleratetreatmentsforpeopleliving
withbraincancernow,andinthefuture,as
quicklyandefficientlyaspossible.
Where do we work?
• InAustraliaandforallpatientsworldwide,
incollaborationwithournationaland
internationalpartners.
How do we work?
• Weareaddingvaluetotheresearchsystemtosupportinnovative
discoveriesandincentivisedrugdevelopmentanddiscoveryinbraincancer.
• Weencouragecollaborativesciencesothatmulti-disciplinaryteamscan
approachproblemsinanewway.Webelievethattheanswersmaybefound
whereexpertisecollidesinunexpectedareas.
• Weaimtoattractthebrightestmindstosolvetheproblemofbraincancer,
toapplytheadvancesthathavebeenmadeinotherareasofmedical
researchtobraincancerresearch.
• Webreakdownbarriers,whethertheyarelocal,internationalorinstitutional
toreduceunnecessaryrepetitionandbenefitfromtheeconomyofscale.
• Wetackleresearchproblemsfromtheperspectiveofpatientstocreatea
patientmovementthatwillshiftthedialthroughadvocacyandfundraising.
• Wearesupportingclinicaltrialstoopenupaccesstonewandexperimental
treatmentstomorepatients.Thisincludessupportforinnovativetrial
designandpersonalisedmedicine,toidentifytherightdrugfortheright
patient,getnewtreatmentstomorepatientsandtodothismuchfaster
thanthetraditionalresearchpathwayallows.
• Wearesupportingbasicandtranslationalresearchtoacceleratediscoveries
fromthelabintotheclinicandtounderstandmoreaboutbraincancerand
howtotreatiteffectively.
Approach
98 PUTTING PATIENTS FIRST
![Page 7: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/7.jpg)
Bycollaboratingbothnationallyandinternationallywecandeliverresults
faster.Weprizecollectivebrainpowerandsupporttheimplementationof
aglobal,multi-disciplinaryresearchcommunity.
Weencouragecollaborationbetweenbraincancerresearchgroupsand
acrossspecialities,includingoncology,nanotechnology,genomics,and
bioinformatics.Workingwithourpartners,wearesettingaglobalresearch
agendatoenablethesharingofresources,reduceunnecessaryduplication,
anddeliverincreasedresearchefficiency.
WehelpfundtheBrainCancerDiscoveryCollaborative,anetworkof
Australianresearchersworkingtogethertoraiseawareness,‘targetthegaps’,
shareknowledge,capacityandresources.
Braincancerisalesscommoncancerandhasmanysub-types,so
internationalcollaborationisvitaltoachievestatisticallysignificantresearch
findingswithinreasonabletimeframes.Globalcollaborationallowsgreater
numbersofpatientstoaccesstrialstoproducestatisticallysignificant
resultsfaster.
Australiaispunchingaboveitsweightwhenitcomestobraincancerresearch
andhasmuchtooffertheglobalresearchcommunity.
Collaborationandborderlessresearch
Collaborationandborderlessresearch
Webelievethatbraincancerresearch needstobeborderless.
– MichelleStewart,HeadofResearchStrategy“ CureBrainCancerhavebeenabsolutelyamazing withthewaythattheyhavebroughttogetherinternationalandnationalcollaborations; we’veneverseenthisbefore.
- A/ProfKerrieMcDonald,CureBrainCancerNeuro-oncologyGroup, LowyCancerResearchCentre,UNSW
“1110 PUTTING PATIENTS FIRST
![Page 8: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/8.jpg)
Ratherthantakinga‘onesizefitsall’approachtotreatmentwecan
now personalise treatments to patients’ individual tumour profiles, deliveringafarmoreeffectivetherapeuticapproach.Thiscouldbea
targetedtherapyoranimmune-basedtherapy,oracombinationofboth.
Biomarkersaremoleculesthatcanbetestedforinaperson’stissuesor
bodyfluidsandanswerimportantquestionsabouttheircancer.Inthe
future,theycouldevenhelpdoctorsdiagnosebraincancerandworkout
whatthebesttreatmentisforeachpatient.Wesupportresearchthat
developsexistingbiomarkerknowledgeandidentifiesadditionalmarkers
inbraincancer,tosupportthedevelopmentofpersonalisedtherapies.
Clinical trials are the best way for patients to access novel treatments, until effective therapies become part of routine care.
CureBrainCancer’svisionisthateverypersondiagnosedwithbraincancer
inAustraliacanaccessnewtreatmentsthroughworld-classclinicaltrials.
Byworkingwithourinternationalpartnerstobringthesetrialshere,weare
enablingaccesstonoveltreatmentsforpatientsinAustraliaatthesame
timeastheyareavailableglobally.
Wearesupportinginnovativetrialdesignthattakesapersonalisedmedicine
approachandenablesresearcherstoidentifytherightdrugforeachpatient
andmakedecisionsfasteraboutwhattreatmentswork.
Thetraditionalresearchpathwayinvolveschangingonevariableatatime
andtestsonetreatmentonmultipleparticipants.Thistakestime,henceit
cantakeupto12yearstogetanexperimentaldrugtomarket.
Inthesenewer,innovativetrialsparticipantsarerandomlyassigned
experimentaltreatmentsbasedontheirgeneticprofiles.Ratherthanthose
variablesremainingthesamefortheentirelifetimeofthetrialirrespective
ofefficacy,patientsarereassigneddifferenttreatmentsbasedonwhat
isworkingforthem.Thiscompressestheresearchtimelineanddelivers
resultsfaster,aswellasenablingthedevelopmentofpersonalisedtherapies,
tailoredtoindividuals.
Furthermore,therearetreatmentsalreadybeingusedonotherdiseases
thatmaybesuitableforbraincancer.Subsidisinginnovativetrialslikethis
willencouragepharmaceuticalcompaniestoseeiftheycanrepurposethese
treatmentsforuseonbraincancer,savingyearsofdevelopmenttime.
Accessto clinicaltrials
Therighttreatmentforeachpatient
Thingshaveacceleratedalotinthelastcoupleofyears. Ithinkwehaveamuchbetterunderstandingofthehumangenomenowandwenowforthefirsttimeinhistoryhavetechnologythatcanactuallyscreenthewholegenomeandcandothiskindofproject.Sowecanscreenhundredsorthousandsofgenesinjustafewhoursforabout$1000.Whereasjustfiveyearsagothatwasalmostimpossible.Soitreallyistechnologydriven, alotoftheresearch.
-DrAndrewMorokoff,RoyalMelbourneHospital,VIC
“
1312 PUTTING PATIENTS FIRST
![Page 9: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/9.jpg)
Discovery funds
Earlystageresearchdevelopsourfundamentalunderstandingofdisease.
Wedonotyetunderstandthediffusenatureofbraincancer,howitis
caused,whyitrecurs,howtotreatitandweareonlyjuststartingto
understandthemarkersofprognosisandresponsetotherapy.
Earlystageresearchisessentialtomovingthefieldofbraincancerforward.
Thisprogramfundsresearchthatwillincreaseourunderstandingofcertain
typesofbraincancer.
Biomarker discovery program
Biomarkersareincreasinglydemonstratingvalueincancer
detection,diagnosis,prognosis,selectionoftherapyandprediction
oftreatmentresponse.
TheCureBrainCancerBiomarkerDiscoveryProgrambringstogether
biomarkerresearchthatisbeingconductedacrossthecountry.
1514 PUTTING PATIENTS FIRST
Clinical trials stimulus program
CureBrainCancer’svisionisthateverypersondiagnosedwithbraincancer
inAustraliacanaccessnewtreatmentsthroughworld-classclinicaltrials.
Weprioritiseinnovativetrialdesignwhichimprovestheprobabilityof
thesuccessofthetrialandlookforoptionsthathavethepotentialto
extendthelivesofpatients.
WesupportinnovativeAustralianideasthathavethepotentialtohelp
patientsgloballyaswellasworkingwithinternationalpartnerstobring
clinicaltrialstoAustraliasothatAustralianshavelocaloptions.
Immunotherapy in action
Immunotherapyharnessesthebody’sownimmunesystemtofightcancer.
Itisagrowingfieldincancerresearch,includingbraincancer,andhasshown
somepromisingresultsinothertypesofcancers.
Paediatric research
BraincancerkillsmorechildrenthananyotherdiseaseinAustraliaso
weareworkingtodevelopnewtreatmentsforchildrenwiththedisease,
whichextendsurvivalbutalsominimisetheharmdonebycurrent
treatmentstoimprovequalityoflife.
Paediatricresearchincludesworkontumourtypesspecifictochildrenand
researchthatisapplicabletopaediatricformsofbraincancermorebroadly.
Brilliant Minds
BrilliantMindsisCureBrainCancer’syoungresearchersupportprogram,
encompassingacommunicationsprogramaswellasanearly-stagecareer
fellowshipprogram.
Itisdesignedtoencouragethebrightestmindsfromacrossdifferent
disciplinesintobraincancerresearchandgrowandsupportthenext
generationofbraincancerresearchers.
ThebiggestchangethatIhaveseeninmyprofessionalcareerhasbeentheincorporationofresearch,andparticularlyclinicaltrials,intothefrontlinetreatmentofchildren.
- ProfStewartJKellie,Paediatriconcologistandneurooncologist, TheChildren’sHospitalatWestmead
“
Ourresearchprograms
![Page 10: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/10.jpg)
Ourstrategyispatient-centricandweworktoempowerpatientssothat
theycanleadfromthefrontincallingforactionandfundingforbraincancer.
WehaveseenfromtheHIVmovementofthepastandstrongadvocacyin
breastcancerhowcriticalandeffectivethepatientvoiceiswhenitcomes
tochangingoutcomes.
The brain cancer community is engaged, passionate and united when it comes to effecting change.
• Increasedlobbyingandadvocacyofpatientgroupsisleadingto
increasedfocus.
• Patientshaveanincreasedappetiteforrisk-takingandtheyare
morevocalincallingforalternatives.
• Enabled,educatedpatientgroups,supportedbynot-for-profits,
arecallingforaccesstoclinicaltrialsandnewtreatments.
• Theinternetasasourceofinformationhasledtoincreasinglyeducated
patients,withcliniciansreportingthatpatientsareaskingforthelatest
treatmentsavailableinternationally.Theinternetcanofcoursebea
hindrance,withlotsofincorrectormisleadinginformation,soweneedto
helppatientsarmthemselveswithknowledgebyactingasaconduitto
reliablesourcesofinformationonbraincancer.
Wefundpriority-drivenresearchthroughacombinationofcompetitive
researchgrantsandbyproactivelyidentifyingpromisingresearchandcritical
knowledgegapsthatdonotfitintotraditionalfundingmechanisms.
Wewillsupportresearchthatcanbetranslatedfrombasicscientificfindings
intotherapeuticinterventionsforpatients.
Through the Cure Brain Cancer application process we aim to provide funding for the projects with the greatest potential impact for patients.
Grantapplicationsareassessedbyourinternationally-renownedScientific
AdvisoryCommittee,whichdecidesonresearchprojectsthatwilldeliver
thatgreatestimpacttopeoplewithbraincancer.TheCommitteecanprovide
adviceaboutresearchinaninternationalcontextandprovideatransparent,
impartialplatformfordecision-makingwhichensuresgoodgovernanceand
safeguardsbestpracticeinresearchfunding.
1716 PUTTING PATIENTS FIRST
Empoweringpatients
In2013mysonGuspassedawayattheageof15afterfightinghisinsidiousbraintumourforthreeandahalfyears.SupportingCureBrainCancermadeusfeellikewehadapurposewhilstwebattledhisillness.CureBrainCanceristheenergysourcestrivingtomakeacurepossible.Ican’twaitforthedaytheirvisionisareality.BysupportingthemIfeellikeIampartofthatrealityforotherfamilies.Icannotwaitforthedaywhenbraincancercanbebeateninsteadofitbeatingus.
- MaryanneLarkin,supporter
“
GRANTS
![Page 11: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/11.jpg)
We have appointed a world-class Scientific Advisory Committee to advise on research funding and policy decisions. Our Committee will:
• Evaluateresearchprojectstofundthatwilldeliverthatgreatestimpact
topatientswithbraincancer.
• Provideadviceaboutresearchinaninternationalcontext,andevaluate
proposalswithglobalvisibility.
• Ensuregoodgovernance.
• Safeguardbestpracticeinresearchfunding.
• ProtecttheintegrityoftheFoundationandprovideatransparent
platformfordecision-making.
Our Committee members are selected on the basis of academic or medical excellence, history of breakthroughs and their commitment to accelerating treatments to people with brain cancer.
The strength of our Committee demonstrates our commitment to responsible spending and the priority that we place on funding the best research with the best chance of success.
CureBrainCancerhasgrownfromaconversationaroundthekitchentable
ofourfounder,CharlieTeo,tobecomethelargestdedicatedfunderofbrain
cancerresearchinAustralia.
Partneringwiththeresearchcommunity,wearesteeringthenationalagenda
–andinfluencingtheglobalagenda–forbraincancerresearch.
Wecouldnotdothiswithoutthesupportofourpartnersandoursupporters,
whoworktirelesslytofundraise,volunteer,arrangeevents,advocateand
takepartinresearch.
Weareproudtobepartofsuchaninspirationalcommunity.
Thankyouforyoursupport.
For more information please contact [email protected]
1918 PUTTING PATIENTS FIRST
SCIENTIFICADVISORYCOMMITTEE CONCLUSION:HOPEFORTHEFUTURE
Professor Webster K. Cavenee, PhD
Director,LudwigInstitutefor
CancerResearch,SanDiego
&DistinguishedProfessor,
UniversityofCaliforniaatSanDiego
Professor Jan Buckner, MD
ProfessorofOncology,
MayoClinicCollegeofMedicine
Chair,DepartmentofOncology,
MayoClinic,Rochester,MN
DeputyDirectorforPractice,
MayoClinicCancerCenter
Professor Mark Rosenthal, MBBS, FRACP, PhD
DirectorofMedicalOncology
atRoyalMelbourneHospital
Dr Helen Wheeler HeadofMedicalOncology,
RoyalNorthShoreHospital
Professor Inder M. Verma
SalkInstituteforBiologicalSciences;
Professor,LaboratoryofGeneticsand
AmericanCancerSocietyProfessor
ofMolecularBiology
Dr Mustafa Khasraw
Medicaloncologistat
RoyalNorthShoreHospitalinSydney
We’veevolvedintoaglobalmovement,alignedtoasingularpurpose,acceleratingtreatmentstopatients.Together,wewillsucceed.
- CatherineStace,CEO,CureBrainCancerFoundation
“
![Page 12: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/12.jpg)
ADDENDUM–Research projectswearefunding
20
MemberoftheBrainCancerDiscoveryCollaborative(BCDC).Molecularimaging.Developingnovel,EphA2targetedPETmolecularimagingtechnologyforglioma.
ForfurtherresearchattheInstituteforMolecularBioscience.PartoftheTrivettPartnershipAgreement.CirculatingmicroRNAasabiomarkerinbraincancer.
Understandinghowepigeneticabnormalitiesleadtobraincancers.ExceptionalresponsetoAvastin.
QueenslandBrainTumourBank. Co-fundedbyTourdeCure.
VisitingAcademicProgramattheLowyCancerResearchCentrewithintheNeuroOncologyGroup.Deputy-directoroftheBrainCancerDiscoveryCollaborative(BCDC).CureBrainCancer Neuro-oncologyGroup.MemberoftheBrainCancerDiscoveryCollaborative(BCDC).PaediatricOncology,fromBenchtoBed.KB004-APhase1andbiodistributionstudyofKB004(ananti-EphA3antibody)inpatientswithglioblastoma.Overcomingresistancetoantibody-drugconjugates inglioblastomapatients.VERTU-Veliparib,radiotherapyandtemozolomideinnewlydiagnosedunmethylatedMGMTglioblastoma.CureBrainCancerHeadofBiomarkerandTranslationalResearchatLowyCancerResearchCentre,UNSWandTeam.ZeroChildhoodCancer. Personalisingtreatmentsforchildrenwithcancer.FortheplanningandsetupofGBMAGILE. TranslationalResearchOfficer.
Phase2StudyofCheckpointBlockadeinPatientsWithGlioblastoma.ConductedatOliviaNewton-JohnCancerResearchInstitute.Deputy-directoroftheBrainCancerDiscoveryCollaborative(BCDC).DirectoroftheBrainCancerDiscoveryCollaborative(BCDC).FundingisinclusiveofdiscretionaryfundsforpromisingprojectswithintheBCDC.Understandingcellularpathways.MemberoftheBrainCancerDiscoveryCollaborative(BCDC).Investigatingtheprocessofcellinvasion.
Targetingtheepidermalgrowthfactorreceptorinhigh-gradeglioma.PharmacologicalinhibitionofMCL-1andBCL-xLtotreathumanmedulloblastoma.NoveltargetedchemotherapeuticagentsagainstDiffuseIntrinsicPontineGliomas(DIPG).YouCanFellowship(SonyFoundation)Newcuresforbraincancer,usingnoveltechnologyforALT-targeteddrugdiscovery.JohnTrivettSeniorResearchFellowshipin BrainCancer.EstablishmentofImmunotherapyCentreofExcellence. KynureninePathwayProject.Co-fundedwith TourDeCure.MicrogliatargetingofGlioblastomaMultiforme(GBM).Establishmentofanewglioma-imagingmodel.DevelopmentofImmunotherapyRoadMap. FundedbyDineForACure.
BiomarkerDiscoveryProgramBiomarkerDiscoveryProgram
BiomarkerDiscoveryProgramBiomarkerDiscoveryProgramBiomarkerDiscoveryProgramBiomarkerDiscoveryProgramBiomarkerDiscoveryProgram
BrilliantMinds
ClinicalTrial StimulusProgram
ClinicalTrial StimulusProgramClinicalTrial StimulusProgram
ClinicalTrial StimulusProgramClinicalTrial StimulusProgramClinicalTrial StimulusProgram
ClinicalTrial StimulusProgramClinicalTrial StimulusProgramClinicalTrial StimulusProgramClinicalTrial StimulusProgram
DiscoveryFunds
DiscoveryFunds
DiscoveryFunds
DiscoveryFunds
DiscoveryFunds
DiscoveryFunds
DiscoveryFunds
DiscoveryFunds Immunotherapy inActionImmunotherapy inActionImmunotherapy inActionImmunotherapy inAction
ProfStephenRoseDrSimonPuttick
ProfBrandonWainwrightDrAndrewMorokoffDrLeeWong
A/ProfKerrieMcDonaldDrSarahOlson
A/ProfKerrieMcDonaldA/ProfKerrieMcDonald
DrNickGottardoDrHuiGan
ProfAndrewScottDrMustafaKhasrawA/ProfKerrieMcDonald
ProfMichelleHaberDrAnnaBarker
A/ProfKerrieMcDonald
ProfAndrewBoydProfTerranceJohns
A/ProfGeraldineO’NeillProfTerranceJohnsProfAndreasStrasserDrMariaTsoli
DrJeremyHenson
Tobeawarded DrHelenWheelerDrSerayAdams
DrManuelGraeberImmunotherapyWorkingGroup
UniversityofQLD
TheUniversityofQueensland Institutefor MolecularBioscienceUniversityof MelbourneMonashUniversity
UniversityofNSW
TheWesley-StAndrew’sResearchInstituteUniversityofNSW
UniversityofNSW
TelethonKid’sResearchInstitute,UWALaTrobeUniversity
LaTrobeUniversity NHMRCClinicalTrialsCentreUniversityofNSW Children’sCancerInstituteAustraliaArizonaStateUniversityUniversityofNSW
CancerResearchInstitute QIMRBerghofer
HudsonInstituteofMedicalResearch
Kid’sResearchInstituteatWestmead
HudsonInstituteofMedicalResearchWalterandElizaHallInstituteChildren’sCancerInstituteAustraliaUniversityofNSW
TheUniversityofQueenslandRoyalNorthShoreHospitalMacquarieUniversity
UniversityofSydney
QLD
QLD QLD
VIC
VIC
NSW
QLD
NSW
NSW
WA
VIC
VIC
NSW
NSW NSW
AUS
NSW
VIC QLD
VIC
NSW
VIC
VIC
NSW
NSW
QLD NSW
NSW
NSW
AUS
3
2
3
2
2
2
3
4
3
3
3
2
3
10.5
4
2
3
2
3
3
3
2
2
1
1
5 2
1
1
1
$466,667 $199,738
$150,000
$199,724
$200,000
$126,500
$120,000
$480,000
$466,667
$516,667
$500,000
$199,233
$498,775
$4,059,917
$1,315,000
$1,200,000
$291,000
$539,000 $566,667
$1,366,667
$416,667
$200,000
$200,000
$180,000
$80,000
$1,250,000 $250,000
$125,000
$30,000
$30,000
BCDC
ProfStephenRose,ProfAndrewBoyd,DrBrettStringer,DrBryanDay ProfAndrewWhittaker,A/ProfStephenMahlerandDrKristoferThurecht TheUniversityofQueensland DrMichaelFay,GenesisCancerCareNewcastlena
A/ProfKateDrummond, DrRodneyLuworDrHsiaoVoon
DrKathrynField
MissEmmaRaymond
ProfPaulKleihaus,ProfPeterBerger
BCDC
BCDC
ProfAndrewScott,DrBryanDay, ProfAndrewBoyd,DrBrettStringer, DrZarnieLwin,DrPoInglisA/ProfHuiGan ProfJohnSimes,ProfMarkRosenthal, A/ProfKerrieMcDonald,DrEngSiewKoh
PukarThapa
A/ProfHuiGan BCDC
BCDC
BCDC
DrFrancineKe,A/ProfAnneVoss
DrDavidZiegler
ProfBrandonWainwright, ProfPerryBartlett
ProfGillesGuillemin
ProfRichardBanati
PROJECT DETAILSPROGRAM LEAD INVESTIGATOR
INSTITUTION STATE TOTAL YEARS OF FUNDING
TOTAL PROJECT COST
CO-INVESTIGATORS
*40% of our funded projects are applicable to paediatric brain cancer
As at February 2016
![Page 13: PUTTING PATIENTS FIRST - Microsoft · The projects we fund include collaborations in more than 40 institutions, across six Australian states and five countries. Through our inaugural](https://reader034.vdocument.in/reader034/viewer/2022042311/5ed9f28128db2d5ca24921bb/html5/thumbnails/13.jpg)
curebraincancer.org.au
[email protected] 1300362965+61295505244
CureBrainCancerFoundation POBox392SurryHillsNSW2010 ABN21121906036
FEB2016CBC0202